The Shanghai Overseas Returned Scholars Association invites the Dutch PhD delegation to visit Medicilon, exploring paths for innovative development together

On July 4^th, the Shanghai Overseas Returned Scholars Association invited the Dutch PhD delegation to visit the Chuansha campus of Shanghai Medicilon Inc. (Medicilon) and held discussions with Medicilon's Founder and CEO, Chunlin Chen, among others. The event was attended by Fang Zou, the Executive Vice President of the Shanghai Overseas Returned Scholars Association, along with officials from the Liaison Department and cadres from the United Front Work Department of the Pudong New Area District Committee.

The Shanghai Overseas Returned Scholars Association invites the Dutch PhD delegation to visit Medicilon, exploring paths for innovative development together.webp

At the beginning of the event, the Dutch PhD delegation eagerly visited Medicilon's laboratory, where they closely observed the advanced equipment and innovative technologies in the field of new drug development. They witnessed the efficient operation of state-of-the-art instruments and the meticulous and scientific approach of the research project teams in their daily work. This immersive experience conveyed the vitality and boundless promise inherent in biopharmaceutical technological innovation.

At the symposium, Dr. Chunlin Chen warmly welcomed the Dutch PhD delegation and briefly introduced Medicilon's development history and its achievements in empowerment. Medicilon has always focused on the field of preclinical research and development. Medicilon has successfully built cutting-edge technology service platforms, including ADC, PROTAC, CGT, small nucleic acids, and antibodies, empowering 480 IND approvals for clinical trials. Additionally, as a co-founder, the first president, and current honorary president of the Biopharmaceutical Branch of the Shanghai Overseas Returned Scholars Association, as well as a returnee entrepreneur, Dr. Chunlin Chen shared his entrepreneurial insights. Dr. Chen extended a sincere invitation to the Dutch PhD attendees, expressing his hope that they would work together to promote the high-quality development of the biopharmaceutical industry.

Subsequently, all parties engaged in a lively and in-depth discussion on the future trends of the biopharmaceutical industry, new models of international collaboration, and hot topics in innovation and entrepreneurship. The participants expressed their commitment to further strengthening communication and collaboration mechanisms, promoting the aggregation and development of various international innovative elements in the Pudong New Area.

The visit of the Dutch PhD delegation to Medicilon not only provided a valuable platform for mutual exchange but also deeply impressed the Dutch scholars with the open, inclusive, collaborative, and innovative entrepreneurial environment in the Pudong New Area. Looking forward to the near future when these Dutch PhDs return to China after their studies, injecting new vitality into the development of biopharmaceutical entrepreneurship and innovation in Pudong.

Looking ahead, Medicilon will steadfastly uphold the spirit of innovation-driven development and open collaboration. Medicilon will actively broaden its international collaboration horizon, deepen strategic partnerships and technical sharing with top talents and institutions both domestically and internationally. By continuously enhancing its research capabilities, establishing and refining its technology service platforms, Medicilon aims to become a globally trusted comprehensive preclinical research and development service CRO. Medicilon strives to provide robust support for the preclinical development of numerous new and effective drugs.

What is preclinical testing?

In the process of preclinical testing of a compound or biological agent into a drug, the compound involved must go through the testing phase. First, we need to identify potential targets that can treat the disease. Then, a variety of compounds or preparations are screened out. Any compound that has shown potential as a drug for the treatment of this disease needs to be tested for toxicity before clinical testing to reduce the possibility of injury. preclinical testing What is the basis of preclinical testing? According to US Food and Drug Administration (FDA) regulations, a series of tests are required before a new drug is approved for use. In the first stage, basic research determines a hypothetical target for the treatment of a certain disease, and then screens small molecules or biological compounds to discover any substance with the potential to treat the disease. Then, a preclinical research phase followed, before which, as described above, the potential toxicity of the compou

阅读全文

Inventory of the three major in vitro pharmacokinetic research methods

The metabolic properties of a compound are an essential factor in whether or not it can be used as a drug in the clinical setting, so pharmacokinetic studies of newly synthesized compounds are required in drug development. In vitro incubation with liver microsomes, recombinant CYP450 enzyme lines, and in vitro incubation with hepatocytes are some of the more common in vitro drug metabolism methods. 1. In vitro incubation method with liver microsomes The metabolic stability and metabolic phenotypes of candidate compounds in different species of liver microsomes are good predictors of the metabolic properties of compounds in vivo. They are practical tools for evaluating candidate compounds in the pre-development phase of drug development. Liver microsomes include rat liver microsomes, human liver microsomes, canine liver microsomes, monkey liver microsomes, and mouse liver microsomes. In in vitro incubation of the liver, microsomes are the "gold standard" for in vitro d

阅读全文

Novel Parkinson’s Therapies Possible with New Mouse Model

Parkinson's disease (PD) is a neurodegenerative disorder that is marked by the accumulation of the protein, α-synuclein (αS), into clumps known as Lewy bodies, which diminish neural health. Now, researchers from Brigham and Women's Hospital (BWH) report the development of a mouse model to induce PD-like αS aggregation, leading to resting tremor and abnormal movement control. The mouse responds to L-DOPA, similarly to patients with PD. The team's study (“Abrogating Native α-Synuclein Tetramers in Mice Causes a L-DOPA-Responsive Motor Syndrome Closely Resembling Parkinson’s Disease”) on the use of this transgenic mouse model appears in Neuron . “α-Synuclein (αS) regulates vesicle exocytosis but forms insoluble deposits in PD. Developing disease-modifying therapies requires animal models that reproduce cardinal features of PD. We recently described a previously unrecognized physiological form of αS, α-helical tetramers, and showed that familial PD-causing missense mutati

阅读全文

Shanghai Medicilon Inc.

搜索此博客